AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35470387 — intervention group
Group type: EXPERIMENTAL
Intervention: High load duration and intensity (75% maximal voluntary isometric contraction for 8 seconds)
Number of subjects: 16
Study 35470387 — intervention group
Group type: COMPARATOR
Intervention: Lower load duration and intensity (35% maximal voluntary isometric contraction for 2 seconds)
Number of subjects: 16
Study 33051240 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell (DC) vaccines
Number of subjects: 35
Study 33051240 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of ICOSL on DCs
Number of subjects: 35
Study 33051240 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular/soluble ICOSL released from vaccine DCs
Number of subjects: 35
Study 33051240 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM10/17 sheddase activity
Number of subjects: 35
Study 35756871 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with atorvastatin calcium tablets (20 mg/d for 15 days), traditional Chinese medicine (TCM) decoctions, and acupuncture therapy once daily for 15 days.
Number of subjects: 0
Study 35756871 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin calcium tablets (20 mg/d for 15 days)
Number of subjects: 0
Study 34003164 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation
Number of subjects: 0
Study 34003164 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraorbital nerve stimulation
Number of subjects: 0
Study 34003164 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote noncephalic electrical stimulation
Number of subjects: 0
Study 34003164 — intervention group
Group type: EXPERIMENTAL
Intervention: External vagus nerve stimulation
Number of subjects: 0
Study 34003164 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 0
Study 32465013 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAD
Number of subjects: 514
Study 36892488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 180
Study 36892488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 180
Study 36892488 — intervention group
Group type: COMPARATOR
Intervention: Guideline Control
Number of subjects: 180
Study 34179937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast walkers (gait speed > 1 m/sec)
Number of subjects: 48
Study 34179937 — intervention group
Group type: COMPARATOR
Intervention: Slow walkers (gait speed < 1 m/sec)
Number of subjects: 48
Study 33661454 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness (negatively phrased)
Number of subjects: 1377
Study 33661454 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness (positively phrased)
Number of subjects: 1377
Study 33661454 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities (positively phrased)
Number of subjects: 1377
Study 33661454 — intervention group
Group type: EXPERIMENTAL
Intervention: General response options interpretation
Number of subjects: 1377
Study 32674250 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g/d oatmeal
Number of subjects: 62
Study 32674250 — intervention group
Group type: COMPARATOR
Intervention: 80 g/d refined white rice
Number of subjects: 62
Study 35569448 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning (n = 205)
Number of subjects: 400
Study 35569448 — intervention group
Group type: COMPARATOR
Intervention: Usual care without prone positioning (control; n = 195)
Number of subjects: 400
Study 34048528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF)
Number of subjects: 3203
Study 35834373 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening strategy with machine learning risk prediction algorithm and diagnostic testing
Number of subjects: 3549300
Study 35834373 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 3549300
Study 32162450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training sessions (6 sessions)
Number of subjects: 70
Study 32162450 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 70
Study 35637604 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI without a waiting period (Group B)
Number of subjects: 167
Study 35637604 — intervention group
Group type: COMPARATOR
Intervention: PVI with a waiting period of 20 min (Group A)
Number of subjects: 167
Study 35637604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 167
Study 34503541 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine disodium salts plus blueberry extract (PCDSB)
Number of subjects: 33
Study 34503541 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM)
Number of subjects: 33
Study 34503541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32731962 — intervention group
Group type: EXPERIMENTAL
Intervention: GII (1 additional feeder)
Number of subjects: 72
Study 32731962 — intervention group
Group type: EXPERIMENTAL
Intervention: GIII (2 additional feeders)
Number of subjects: 72
Study 32731962 — intervention group
Group type: EXPERIMENTAL
Intervention: GIV (3 additional feeders)
Number of subjects: 72
Study 32731962 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional feeders)
Number of subjects: 72
Study 35360949 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted bi-unicompartmental knee arthroplasty (bi-UKA)
Number of subjects: 76
Study 35360949 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (TKA)
Number of subjects: 76
Study 35360949 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm-assisted bi-UKA
Number of subjects: 76
Study 33991868 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for treatment adherence and symptom management
Number of subjects: 77
Study 33991868 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study 36008246 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training program
Number of subjects: 52
Study 36008246 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatments
Number of subjects: 52
Study 33737070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 33737070 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatments
Number of subjects: 0
Study 36454676 — intervention group
Group type: EXPERIMENTAL
Intervention: Load carriage treadmill exercise (30% body mass; 22.4 ± 3.7 kg)
Number of subjects: 20
Study 34174551 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine (0.5 mg) with low menthol (0.5%)
Number of subjects: 38
Study 34174551 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine (0.25 mg) with low menthol (0.5%)
Number of subjects: 38
Study 34174551 — intervention group
Group type: COMPARATOR
Intervention: Saline control (0.0 mg) with low menthol (0.5%)
Number of subjects: 38
Study 34174551 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine (0.5 mg) with saline control (0.0%)
Number of subjects: 38
Study 34174551 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine (0.25 mg) with saline control (0.0%)
Number of subjects: 38
Study 32947587 — intervention group
Group type: EXPERIMENTAL
Intervention: Running subcuticular closure
Number of subjects: 75
Study 32947587 — intervention group
Group type: COMPARATOR
Intervention: Simple, horizontal mattress, vertical mattress, and AD techniques
Number of subjects: 75
Study 35320813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-pressure resistance training
Number of subjects: 0
Study 35320813 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing rehabilitation treatment
Number of subjects: 0
Study 35325449 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve + Rossetti Fundoplication (SG + RF)
Number of subjects: 138
Study 32224489 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-focused internet-based psychodynamic therapy (IPDT) for 8 weeks
Number of subjects: 76
Study 32224489 — intervention group
Group type: COMPARATOR
Intervention: Supportive control for 8 weeks
Number of subjects: 76
Study 33278179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 0
Study 33278179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0
Study 33278179 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 34582037 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of ropivacaine 0.2% at 6 ml/h
Number of subjects: 81
Study 34582037 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed, intermittent boluses of ropivacaine 0.2% at 10 ml every 8th hour
Number of subjects: 81
Study 34582037 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 81
Study 34582037 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed, intermittent boluses
Number of subjects: 81
Study 34174225 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Anthropomorphic Movement Training (EAMT) therapy
Number of subjects: 20
Study 34174225 — intervention group
Group type: COMPARATOR
Intervention: Conventional upper limb therapy
Number of subjects: 20
Study 36170964 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g milk protein (MILK)
Number of subjects: 24
Study 36170964 — intervention group
Group type: COMPARATOR
Intervention: 30 g plant-derived protein blend (PLANT-BLEND) combining 15 g wheat, 7.5 g corn, and 7.5 g pea protein
Number of subjects: 24
Study 36170964 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MILK and PLANT-BLEND
Number of subjects: 24
Study 33471564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) 2.0 mg
Number of subjects: 49
Study 33471564 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg
Number of subjects: 49
Study 32392169 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplane imaging
Number of subjects: 430
Study 34231450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 163
Study 34231450 — intervention group
Group type: COMPARATOR
Intervention: Attention- and time-matched control
Number of subjects: 163
Study 34420947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 133
Study 32557601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg single-dose
Number of subjects: 0
Study 32557601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple 400 mg ribociclib doses
Number of subjects: 0
Study 32557601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple 600 mg ribociclib doses
Number of subjects: 0
Study 32557601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir with ribociclib 600 mg multiple doses
Number of subjects: 0
Study 35986262 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-based education
Number of subjects: 168
Study 35986262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based education
Number of subjects: 168
Study 35986262 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 168
Study 35986262 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between SMS and group-based education
Number of subjects: 168
Study 33783964 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 536
Study 33783964 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (Lantus; IGlar)
Number of subjects: 536
Study 32083368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone (cardioversion)
Number of subjects: 1237
Study 32083368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone (non-cardioversion)
Number of subjects: 1237
Study 32083368 — intervention group
Group type: COMPARATOR
Intervention: Dronedarone
Number of subjects: 1237
Study 36441735 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model‐Based Intervention (HEBI) module
Number of subjects: 284
Study 36441735 — intervention group
Group type: COMPARATOR
Intervention: Health talk on non‐communicable disease (Control)
Number of subjects: 284
Study 35751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in PD patients
Number of subjects: 47
Study 35751029 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in NPD patients
Number of subjects: 47
Study 35751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Probit analysis of remifentanil in PD patients
Number of subjects: 47
Study 35751029 — intervention group
Group type: COMPARATOR
Intervention: Probit analysis of remifentanil in NPD patients
Number of subjects: 47
Study 32620620 — intervention group
Group type: EXPERIMENTAL
Intervention: Second primary endometrial cancer (SPEC) patients with greater than a 10-year interval from prior malignancy
Number of subjects: 326
Study 32620620 — intervention group
Group type: COMPARATOR
Intervention: First primary endometrial cancer (FPEC) patients
Number of subjects: 326
Study 35312741 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 0
Study 35312741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression among female sex workers
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Life stress
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with HIV
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal abuse
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of sexual services from clients' homes
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a non-barrier modern family planning method
Number of subjects: 300
Study 34120613 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of alcohol
Number of subjects: 300
Study 33586144 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral (RUL) ECT
Number of subjects: 138
Study 33586144 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal (BT) ECT
Number of subjects: 138
Study 35587720 — intervention group
Group type: EXPERIMENTAL
Intervention: INDDEX24
Number of subjects: 234
Study 35587720 — intervention group
Group type: COMPARATOR
Intervention: PAPI
Number of subjects: 234
Study 34411872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT), 8-week group-based counseling sessions
Number of subjects: 42
Study 34411872 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study 34864864 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat packing
Number of subjects: 101
Study 34864864 — intervention group
Group type: COMPARATOR
Intervention: No throat packing
Number of subjects: 101
Study 33532993 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at 30 min interval
Number of subjects: 20
Study 33532993 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at more than 30 min interval
Number of subjects: 20
Study 33532993 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB regimen
Number of subjects: 20
Study 35451604 — intervention group
Group type: EXPERIMENTAL
Intervention: READ training
Number of subjects: 570
Study 35351058 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized radiotherapy (RT) using PSMA-PET
Number of subjects: 50
Study 35351058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment project for training of bladder preparation
Number of subjects: 50
Study 35351058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial investigating safety of PSMA-PET for focal dose escalation RT
Number of subjects: 50
Study 35351058 — intervention group
Group type: EXPERIMENTAL
Intervention: In-silico RT planning studies
Number of subjects: 50
Study 35351058 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral sparing in focal dose escalation
Number of subjects: 50
Study 32106189 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality curriculum (30-minute session using OculusRift headset)
Number of subjects: 168
Study 35089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea containing 550 mg mulberry leaf extract (MLE), 3 times a day for 4 weeks
Number of subjects: 48
Study 35089999 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (green tea not containing MLE), 3 times a day for 4 weeks
Number of subjects: 48
Study 32854125 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate operative therapy
Number of subjects: 154
Study 32854125 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative risk factors (leukocytosis, increased CRP-level, bi- or trimalleolar fracture type)
Number of subjects: 154
Study 32854125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus and elevated ASA score
Number of subjects: 154
Study 32854125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic models for prolonged LOS and postoperative complications
Number of subjects: 154
Study 36190440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 20 mg (adjusted to 34 or 10 mg between weeks 2-8)
Number of subjects: 0
Study 36190440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34498304 — intervention group
Group type: EXPERIMENTAL
Intervention: MaiStep delivered by psychologists or teachers (IG-T)
Number of subjects: 1654
Study 34498304 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 1654
Study 35098659 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and problem solving
Number of subjects: 342
Study 35098659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural case management
Number of subjects: 342
Study 35098659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 342
Study 35098659 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids or low-dose antipsychotic medication (fast-fail option)
Number of subjects: 342
Study 33019891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa) or >30 ng/mL (group IIb)
Number of subjects: 102
Study 33019891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa)
Number of subjects: 102
Study 33019891 — intervention group
Group type: COMPARATOR
Intervention: No preoperative vitamin D supplementation (group I)
Number of subjects: 102
Study 32898192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg tablet formulation (F-15)
Number of subjects: 12
Study 32898192 — intervention group
Group type: COMPARATOR
Intervention: Marketed brand (ACEMED)
Number of subjects: 12
Study 32898192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study 34723864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mg/kg ideal body weight)
Number of subjects: 34
Study 34723864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 34
Study 34723864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 34
Study 32269278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 57
Study 32269278 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 57
Study 34674610 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized extract of Calendula officinalis L. (SEC)
Number of subjects: 40
Study 34674610 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (Control Group)
Number of subjects: 40
Study 33781304 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask use
Number of subjects: 0
Study 33781304 — intervention group
Group type: EXPERIMENTAL
Intervention: Underpowered trials
Number of subjects: 0
Study 33781304 — intervention group
Group type: EXPERIMENTAL
Intervention: No trials
Number of subjects: 0
Study 32187097 — intervention group
Group type: EXPERIMENTAL
Intervention: Local multimodal drug injection (ropivacaine 10 mL, morphine 5 mL, ceftezole 5 mL, normal saline 5 mL)
Number of subjects: 101
Study 32187097 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 101
Study 32187097 — intervention group
Group type: EXPERIMENTAL
Intervention: Local multimodal drug injection
Number of subjects: 101
Study 35206123 — intervention group
Group type: EXPERIMENTAL
Intervention: Abriendo Caminos intervention
Number of subjects: 365
Study 33935137 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug comorbidity index
Number of subjects: 598664
Study 33935137 — intervention group
Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 598664
Study 35976205 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaha System-based continuing care
Number of subjects: 100
Study 35976205 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 100
Study 32036960 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary Met level (45% of Lys content)
Number of subjects: 108
Study 32036960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest Arg level (90% of Lys content)
Number of subjects: 108
Study 32036960 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest Arg level (110% of Lys content)
Number of subjects: 108
Study 33962902 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily delivery of a single whole egg per day added to local standard nutrition care for 6 months
Number of subjects: 1200
Study 33962902 — intervention group
Group type: COMPARATOR
Intervention: Local standard nutrition care package alone
Number of subjects: 1200